Qiagen N : Virtual Berenberg MDx Day Investor Introduction

Making improvements in life possible

Investor introduction

May 2024

Forward looking statements

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be, deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, adjusted diluted earnings per share results, product launches (including anticipated launches of next generation sequencing solutions, the QIAstat-Dx syndromic testing platform, a gastrointestinal panel in the U.S., and a CE-IVD marked panel for meningitis for the QIAstat-Dx syndromic testing platform, along with the QuantiFERON-based tests for tuberculosis and Lyme disease), placements of QIAsymphony system, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; and the other factors discussed under the heading "Risks and Risk Management" in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted gross income, adjusted net income, adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted operating margin, adjusted net income before taxes, adjusted income tax, adjusted tax rate, adjusted EBITDA, adjusted EPS, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation "Reconciliation of Non-GAAP to GAAP Measures" for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-lookingnon-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-lookingnon-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN's GAAP results.

Investor Introduction

Our Vision

Making improvements in life possible

Our Mission

Enabling access to valuable insights from molecular research to clinical healthcare

Bichat-Claude Bernard Hospital, Paris

Investor Introduction

QIAGEN at a glance

A global company with scale

$1.97 billion 2023

sales

Highly recurring revenues

~52%

Americas

Sales~32%

(2023)EMEA

~16%

Asia-Pacific / Japan

Balanced customer markets

~6,000

employees known as QIAGENers

~ 88%

Consumables and related revenues

~12% ~ 50%

InstrumentsMolecular

Diagnostics

• 50%

Life

Sciences

>500,000

customers worldwide

Investor Introduction

QIAGEN solutions are used across the world by researchers - from young scientists to Nobel laureates - and clinical testing labs

Investor Introduction

QIAGEN products are known for the highest quality

Investing ~9-10% of sales in R&D and best-in-class manufacturing

Investor Introduction

In the right place at the right time

Addressable market

Leveraging the continuum of research to clinical healthcare to maximize opportunities

	Life Sciences		Molecular Diagnostics
Academia	Pharma	Applied testing	Infectious disease	Immune response	Oncology

~$5 billion (1)

~$6 billion(1)

Molecular market drivers

Key customers

• Academic labs
• Government research

• Continuous waves of innovation (e.g. Liquid biopsy, MRD, wastewater testing, immuno-oncology)
• Aging population - complex health conditions, prevention and treatment
• Diseases becoming more chronic
• Growing demand for genetic testing
• Increasing prevalence of infectious diseases

•	Big Pharma	•	Human ID /	•	Hospitals
•	CROs		Forensics	•	Reference labs
•	Biotech	•	Food testing	•	Decentralized healthcare settings

1) Based on 2020 QIAGEN estimates

CRO - Contract Research Organizations

MRD - Minimal Residual Disease

Investor Introduction

Providing Sample to Insight solutions to uncover molecular insights

Sample technologies

Assay technologies

Sample to Insight solutions

Biological	Automation systems	Bioinformatics	Valuable
molecular
sample
		insights

Discovery research

Advancing understanding of life

Pharma

Faster and better drug R&D

Clinical diagnostics

Accurate disease diagnosis

Companion Diagnostics

Better precision medicine

Human Identification

Improving public safety

Investor Introduction

Leveraging leadership from the first step in any laboratory

Biological

sample

Sample preparation

(DNA / RNA extraction)

No. 1

Sample

technologies

Leading portfolio of

instruments and

consumables

The most critical step in molecular workflows

Differentiated solutions for modular and integrated workflows

Unmatched time to result, scalability and ease of use

Platform-agnostic consumables

Detection

(Technologies to unlock insights)

Top 3

PCR

No. 2

Digital

PCR

No. 1

Data analysis / interpretation

Top 3

NGS

No. 1

Valuable

molecular

insights

Addressing high-growth applications

	Liquid biopsy	Cell and Gene	Multi-omics	Multi-plex	MRD	Companion Dx
Microbiome	(Minimal Residual
therapy	testing
			Disease)

Investor Introduction

Life Sciences: Working to enable scientific advancements

	QIAGEN value
Academic research	2023 sales
	~$930 million
Pharma development	Recognized innovator
	supporting scientific
	breakthroughs
Applied testing	Able to translate innovations
into commercial products

Selected QIAGEN products

Sample technologies		Assay technologies	Instruments
~300 consumables kits		•	Real-time PCR enzymes	•	QIAsymphony
for processing:			and panels	•	QIAcube Connect
• Tissue, blood, bone, cells,		• QIAcuity digital PCR kits	•	EZ2 Connect
	plants, soil, microbiome, other		•	QIAseq Next-Generation	•	QIAcuity digital PCR
				Sequencing kits	•	RotorGene Q

~$5 billion

addressable market

Bioinformatics

• Ingenuity Pathway Analysis (IPA)
• CLC Genomics Workbench
• • Microbial Genomics
  • Metagenomics
  • Single Cell Genomics

Investor Introduction